摘要
[目的]探讨肺癌患者血清可溶性Apo-1/Fas(sApo-1/Fas)浓度的变化及其在临床上的应用价值。[方法]采用酶联免疫吸附试验法(ELISA)对60例肺癌患者以及31例正常人sApo-1/Fas浓度进行了检测,并比较41例肺癌患者手术前后血清sApo-1/Fas浓度。[结果]肺癌患者血清sApo-1/Fas浓度明显高于正常对照组(P<0.01),血清sApo鄄1/Fas浓度与临床分期有关,与肺癌患者性别、年龄、病理类型无相关,Ⅳ期肺癌血清sApo鄄1/Fas浓度明显高于其他各期(P<0.05或P<0.01),Ⅲ期明显高于Ⅱ期(P<0.05),Ⅱ期明显高于Ⅰ期(P<0.01),Ⅰ期与正常对照组比较差异无显著性(P>0.05);手术后肺癌患者血清sApo-1/Fas浓度低于手术前(P<0.01)。[结论]血清sApo-1/Fas检测可能对指导肺癌治疗、判断预后有积极临床意义。
To study the changes of serum soluble Apo-1/Fas(sApo-1/Fas)in patients with lung cancer and its clinical value.Enzyme linked immunosorbent assays(ELISA)were available to detect the level of sApo-1/Fas in60cases of pa-tients with lung cancer and31cases of normal control subject,compared with41patients with lung cancer pre-and post-operation.Level of sApo-1/Fas were elevated in patients with lung cancer compared to the controls(P<0.01),sApo-1/Fas was correlat-ed with clinical stage,and not with gender,age and pathologic types;the sApo-1/Fas level in stageⅣwas higher in comparision with stageⅢ,ⅡandⅠ(P<0.05～0.01),in stageⅢit was higher than that in stageⅡandⅠ(P<0.05),and in stageⅡit was higher than that in stageⅠ(P<0.05),but no significant difference was found between stageⅠand normal control subject.And the sApo-1/Fas levels were remarkably reduced in patients with lung cancer after operation(P<0.01).[Conclusion]Detection of sApo-1/Fas may play role for cancer therapy and predict prognosis in lung cancer
出处
《肿瘤学杂志》
CAS
2003年第3期128-129,共2页
Journal of Chinese Oncology
